← Back to patent-cliff list
RP-7214
Tier C — Watch / tradeRP-7214
Rhizen Pharmaceuticals Sa
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：DHODH
Indications (approved)：COVID-19, Myelodysplastic syndrome, Acute myeloid leukaemia, Chronic myelomonocytic leukaemia
Regional status
US
No progress
2020-12-29
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of RP-7214?
Approved indications include: COVID-19, Myelodysplastic syndrome, Acute myeloid leukaemia, Chronic myelomonocytic leukaemia.
When does the RP-7214 patent expire?
No public expiry year is available for RP-7214 yet; this page updates once verified.
How do I get a quote for RP-7214 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21